M. Bar

发表

Expanding spectrum of the association between Type 1 Gaucher disease and cancers: A series of patients with up to 3 sequential cancers of multiple types—Correlation with genotype and phenotype

D. Jain, P. Mistry, G. Pastores, 2010, American journal of hematology.

Pathogenesis of pulmonary edema during interleukin-2 therapy: correlation of chest radiographic and clinical findings in 54 patients.

W. Webb, G. Gamsu, J. Klein, 1991, AJR. American journal of roentgenology.

A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.

M. Atkins, J. Doroshow, G. Weiss, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells.

M. Atkins, M. Sznol, M. B. Atkins, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance

Omar H. Butt, Alokkumar Jha, M. Bonnen, 2020, Cancer Cell.

Combined Fludarabine and Rituximab for Low Grade Lymphoma and Chronic Lymphocytic Leukemia

D. Heitjan, C. Hesdorffer, D. Savage, 2003, Leukemia & lymphoma.

Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen.

R. Fisher, M. Bar, G. Weiss, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma.

R. Fisher, J. Doroshow, G. Weiss, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sporadic phaeochromocytomas are rarely associated with germline mutations in the von Hippel‐Lindau and RET genes

M. Bar, E. Friedman, I. Lerer, 1997, Clinical endocrinology.

Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment

D. Siegel, W. Pierceall, D. Reece, 2020, Leukemia.

Long‐term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non‐Hodgkin lymphoma

A. LaCasce, J. Friedberg, J. Leonard, 2017, British journal of haematology.

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Alokkumar Jha, M. Bonnen, S. Shete, 2020, The Lancet.

Disseminated Pneumocystis carinii infection in a patient with acquired immunodeficiency syndrome.

A. Dwork, M. Grimes, H. Wasserman, 1987, Human pathology.

Pomalidomide, Dexamethasone, and Daratumumab after Lenalidomide Treatment in Relapsed Refractory Multiple Myeloma: Updated Results from an Open-Label, Multicenter, Phase 2 Trial

D. Siegel, D. Reece, A. Agarwal, 2020 .

Pomalidomide (POM) + low-dose dexamethasone (LoDEX) + daratumumab (DARA) in relapsed and/or refractory multiple myeloma (RRMM) after lenalidomide (LEN)-based treatment (Tx) failure.

D. Siegel, D. Reece, G. Schiller, 2018 .

A phase I study of high-dose interleukin-2 in combination with interferon-alpha 2b.

M. Atkins, G. Weiss, J. Sparano, 1990, Journal of biological response modifiers.

Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial.

A. Jakubowiak, A. Krishnan, S. Lonial, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Psychological support to an autologous bone marrow transplant unit in a community hospital: a pilot experience

Martha A. Williams, M. Bar, I. Tepler, 1998, Psycho-oncology.

Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2 MM-014 trial

D. Siegel, D. Reece, A. Agarwal, 2022, Leukemia & lymphoma.

Pomalidomide + Low-Dose Dexamethasone + Daratumumab in Relapsed and/or Refractory Multiple Myeloma after Lenalidomide-Based Treatment Failure

D. Siegel, D. Reece, A. Agarwal, 2018, Blood.

Phase I/II Results of a Multicenter Trial of Perifosine (KRX-0401) + Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma Who Were Previously Relapsed from or Refractory to Bortezomib

A. Jakubowiak, A. Krishnan, S. Lonial, 2008 .

Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma

Philip S. Yu, Sharon S. Choi, Omar H. Butt, 2023, BMC Cancer.

Phase II trial of high-dose interleukin-2 and lymphokine-activated killer cells in Hodgkin's disease and non-Hodgkin's lymphoma.

R. Fisher, M. Atkins, J. Doroshow, 1991, Journal of immunotherapy : official journal of the Society for Biological Therapy.

Immune Profiling of Relapsed or Refractory Multiple Myeloma Patients Treated with Pomalidomide and Low-Dose Dexamethasone in Combination with Daratumumab

D. Siegel, W. Pierceall, D. Reece, 2018, Blood.

Immune Profile of Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Treated with Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) + Daratumumab (DARA) in the Second Line Immediately after Lenalidomide (LEN)

D. Reece, A. Agarwal, G. Schiller, 2017 .